Fresenius SE & Co. KGaA has acquired the remaining 45% of mAbxience from Insud Pharma, securing full ownership of the biosimilars company and opening what it described as a new phase of growth.
Fresenius first acquired a 55% majority stake in mAbxience in August 2022 and has consolidated the business since then. The platform is now wholly owned within Fresenius Kabi’s Biopharma business, which spans development, manufacturing and commercialization.
The companies said full ownership creates a stronger platform for quality, supply resilience, innovation and wider patient access to high-quality biosimilars as a major wave of biologics approaches loss of exclusivity.
Michael Sen, CEO of Fresenius, said, “Full ownership gives us complete control over cost, capacity and launch timing, and full economic benefit, as the next wave of biologics loses exclusivity. For patients, that means dependable access to high-quality biosimilars; for shareholders, it is a disciplined investment in a business we know well.”
Jurgen van Broeck, CEO of mAbxience, said, “The success of mAbxience today is built on the vision, dedication and hard work of many people who have contributed to this journey from the very beginning. Full ownership is the natural next step and creates an even stronger platform for innovation, growth and long-term impact for patients, customers, and partners. As we begin this next chapter together, we will continue to build on the entrepreneurial spirit, scientific expertise and commitment to patients that have driven mAbxience’s success.”
mAbxience said it will continue supporting existing customers and partners while maintaining quality, reliable supply and its ongoing commitments worldwide.
Jurgen van Broeck will continue to lead mAbxience and report to Dr. Sang-Jin Pak, President Biopharma at Fresenius.
Other Pharma Industry Acquisitions
Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.